Pharmacologic management of opioid withdrawal symptoms can reduce the intensity of drug craving and improve treatment retention in patients with opioid use disorder who will receive maintenance treatment.…
Med Lett Drugs Ther. 2018 Aug 27; 60(1554):137-42
Pharmacologic management of opioid withdrawal symptoms can reduce the intensity of drug craving and improve treatment retention in patients with opioid use disorder who will receive maintenance treatment. Withdrawal management without subsequent maintenance treatment is associated with high rates of relapse, overdose death, and HIV and/or hepatitis C virus infection. Several guidelines on management of opioid withdrawal are available. Maintenance treatment of opioid use disorder was reviewed in a previous issue.
The FDA has approved lofexidine ( Lucemyra – US WorldMeds/Salix), a centrally acting alpha 2 receptor agonist, to manage withdrawal symptoms in adults abruptly stopping opioid use. Available in the UK since…
Med Lett Drugs Ther. 2018 Jul 16; 60(1551):115-7
The FDA has approved lofexidine ( Lucemyra – US WorldMeds/Salix), a centrally acting alpha 2 receptor agonist, to manage withdrawal symptoms in adults abruptly stopping opioid use. Available in the UK since 1992, lofexidine is the first nonopioid to be approved in the US for management of opioid withdrawal symptoms. Clonidine ( Catapres , and generics), another central alpha 2 receptor agonist, has been used off-label for this indication for many years.
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne…
Med Lett Drugs Ther. 2017 Jun 5; 59(1522):89-96
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the CDC, there were 33,091 deaths related to opioid overdose in the US in 2015, more than in any previous year. Several guidelines on the management of opioid use disorder have recently been published.
The FDA has approved a buccal film formulation of the partial opioid agonist buprenorphine combined with the opioid antagonist naloxone ( Bunavail – BioDelivery Sciences) for maintenance treatment of opioid…
Med Lett Drugs Ther. 2015 Feb 2; 57(1461):19-20
The FDA has approved a buccal film formulation of the partial opioid agonist buprenorphine combined with the opioid antagonist naloxone ( Bunavail – BioDelivery Sciences) for maintenance treatment of opioid dependence. Sublingual tablet and film formulations of the same combination were approved earlier. The manufacturer of Bunavail claims that the new product is superior to sublingual formulations because of the convenience of buccal administration and better absorption into the blood, permitting use of lower doses.
A new sublingual tablet formulation of the partial opioid agonist buprenorphine combined with the opioid antagonist naloxone ( Zubsolv – Orexo) has been approved by the FDA for maintenance treatment of…